SCHEMBL4672028

SCHEMBL4672028

O=C(C=C(O)c1nc[nH]n1)c1nc(S(=O)(=O)c2ccc(Cl)cc2)cs1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.34
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
NAMPT P43490 1/20 0.31
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 3/20 0.30
HSP90AA1 P07900 2/20 0.30
CHEK2 O96017 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPK1 P28482 1/20 0.30
NPC1 O15118 1/20 0.30
ADRB2 P07550 1/20 0.30
MAPT P10636 1/20 0.30
XBP1 P17861 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TLR9 Q9NR96 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673938 0.91 LOXL2 (0.33) AKR1B1SMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4672156 0.90 HTR2A (0.36) AKR1B1KMT2A
SCHEMBL4678135 0.84 AKR1B1 (0.34) AKR1B1HTTSMN1; SMN2KDM4EPKM
SCHEMBL4672762 0.82 NPC1 (0.31) AKR1B1ALDH1A1CHEK2CYP3A4MAPK1
SCHEMBL4680017 0.80 ALDH1A1 (0.33) AKR1B1HTTSMN1; SMN2L3MBTL1NAMPT
SCHEMBL4679590 0.80 CHEK2 (0.32) AKR1B1SMN1; SMN2KMT2AALDH1A1CHEK2
SCHEMBL4674434 0.79 AKR1B1 (0.41) AKR1B1HTTSMN1; SMN2KDM4EPKM
SCHEMBL4673680 0.79 ALDH1A1 (0.38) AKR1B1HTTSMN1; SMN2KDM4EPKM
SCHEMBL4673676 0.79 ALDH1A1 (0.38) AKR1B1HTTSMN1; SMN2KDM4EPKM
SCHEMBL4676012 0.78 MAPT (0.41) AKR1B1KDM4EKMT2AALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1B1 17/4885HTT 1204/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.